Faricimab
- Generic Name
- Faricimab
- Brand Names
- Vabysmo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1607793-29-2
- Unique Ingredient Identifier
- QC4F7FKK7I
- Background
Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV). Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies such as...
- Indication
Faricimab is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).
- Associated Conditions
- Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD), Visual Impairment
- Associated Therapies
- -
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
- Conditions
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 850
- Registration Number
- NCT06680817
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients
- Conditions
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Target Recruit Count
- 30
- Registration Number
- NCT06572553
- Locations
- 🇨🇳
2 nd Affiliated Hospital, School of Medicine, Zhejiang University, China, Hanzhou, Zhejiang, China
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
- Conditions
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT06439576
- Locations
- 🇨🇳
Qingdao Eye Hospital of Shandong First Medical University, Qingdao, China
🇨🇳Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology; Opthamology, Wuhan, China
🇨🇳Hebei Eye Hospital, Xingtai, China
Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.
- Conditions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06271330
- Locations
- 🇫🇷
Ducloyer, Nantes, France
Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 13
- Registration Number
- NCT06231121
- Locations
- 🇩🇰
Miklos Schneider, Glostrup, Denmark
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
- Conditions
- Interventions
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 280
- Registration Number
- NCT06176352
- Locations
- 🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of
🇦🇺South West Retina, Liverpool, New South Wales, Australia
🇦🇺Strathfield Retina Clinic, Strathfield, New South Wales, Australia
Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 46
- Registration Number
- NCT06124677
- Locations
- 🇩🇰
Miklos Schneider, Glostrup, Denmark
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Jaeb Center for Health Research
- Target Recruit Count
- 600
- Registration Number
- NCT05844982
- Locations
- 🇺🇸
IL Eye and Ear Infirmary-University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Retina Associates of Florida, LLC, Tampa, Florida, United States
🇺🇸Midwest Eye Institute, Indianapolis, Indiana, United States
Safety and Efficacy of Faricimab in Patients With NPDR
- Conditions
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Greater Houston Retina Research
- Target Recruit Count
- 150
- Registration Number
- NCT05681884
- Locations
- 🇺🇸
Retina Group of Florida, Sarasota, Florida, United States
🇺🇸Mississippi Retina Associates, Jackson, Mississippi, United States
🇺🇸Retina Consultants of Texas, The Woodlands, Texas, United States
Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 446
- Registration Number
- NCT05610319
- Locations
- 🇺🇸
Retinal Consultants Medical Group Inc., Modesto, California, United States
🇺🇸Vitreo-Retina Medical Group, Sacramento, California, United States
🇺🇸University Retina and Macula Associates, Oak Forest, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.